Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleThe use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research.
Author(s)Grinspoon L, Bakalar JB.
Journal, Volume, IssueJ Psychoactive Drugs. 1998 Apr-Jun;30(2):171-7.
Major outcome(s)A number of patients find cannabis (marihuana) useful in the treatment of their bipolar disorder
IndicationBipolar disordersAbstract

The authors present case histories indicating that a number of patients find cannabis (marihuana) useful in the treatment of their bipolar disorder. Some used it to treat mania, depression, or both. They stated that it was more effective than conventional drugs, or helped relieve the side effects of those drugs. One woman found that cannabis curbed her manic rages; she and her husband have worked to make it legally available as a medicine. Others described the use of cannabis as a supplement to lithium (allowing reduced consumption) or for relief of lithium's side effects. Another case illustrates the fact that medical cannabis users are in danger of arrest, especially when children are encouraged to inform on parents by some drug prevention programs. An analogy is drawn between the status of cannabis today and that of lithium in the early 1950s, when its effect on mania had been discovered but there were no controlled studies. In the case of cannabis, the law has made such studies almost impossible, and the only available evidence is anecdotal. The potential for cannabis as a treatment for bipolar disorder unfortunately can not be fully explored in the present social circumstances.

Dose(s)self dosing
Duration (days)
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, USA.
Full text

[Back to Overview]  [IACM Homepage]